6-甲氧基-1H-吲唑 | 3522-07-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 6-甲氧基-1H-吲唑
• 英文名称: 6-methoxy-1H-indazole
• 英文别名: 6-methoxyindazole
• CAS: 3522-07-4
• 化学式: C₈H₈N₂O
• mdl: MFCD09261132
• 分子量: 148.164
• InChiKey: CYEQSOYROKGJDA-UHFFFAOYSA-N

物化性质

• 熔点：
  97-99 °C
• 沸点：
  312.5±15.0 °C(Predicted)
• 密度：
  1.244±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存放条件：室温且干燥环境下

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Methoxy-1h-indazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Methoxy-1h-indazole
CAS number: 3522-07-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8N2O
Molecular weight: 148.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

6-甲氧基-1H-吲唑是一种医药中间体。

制备

6-甲氧基-1H-吲唑可通过2-氟-4-甲氧基苯甲醛与肼的关环反应制备。具体步骤如下：将2-氟-4-甲氧基苯甲醛（2.0克，12.97毫摩尔）溶解于四氢呋喃（THF，20.0毫升）中，并在搅拌下滴加肼（12.9毫升，410.5毫摩尔）。随后，在95℃至110℃下搅拌混合物3天。反应完成后，将溶液浓缩至体积的三分之一，然后加入水以促进产物沉淀。过滤得到的固体，并用大量水洗涤后在真空烘箱中干燥，最终获得白色固体状化合物6-甲氧基-1H-吲唑（1.25克，产率65%）。

反应信息

• 作为反应物：
  描述：

  6-甲氧基-1H-吲唑 在 1,1'-双(二苯基膦)二茂铁 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 碘 、 三乙胺 、 potassium hydroxide 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 20.0~70.0 ℃ 、100.0 kPa 条件下， 反应 1.0h， 生成 6-甲氧基-1H-吲唑-3-羧酸甲酯
  参考文献：
  名称：

  通过钯催化3-碘吲唑羰基化反应合成3-吲唑羧酸酯和酰胺

  摘要：

  开发了一种简单有效的制备1 H-吲哚-3-羧酸酯和酰胺的方法。在甲醇或胺的存在下，对一系列官能化的3-碘吲唑进行Pd催化的羰基化反应，以中等至良好的收率得到标题化合物。对于大多数实例，反应在温和条件下干净地进行，该条件易于被允许进一步合成转化的多种官能团所耐受。 羰基化-酯-酰胺-烷氧基羰基化-氨基羰基化-碘吲唑-钯催化

  DOI：

  10.1055/s-0030-1260199
• 作为产物：
  描述：

  对氟苯甲醚 在 氢氧化钾 、 2,2,6,6-tetramethylpiperidinyl-lithium 作用下， 以 乙醚 、 乙醇 、 正己烷 为溶剂， 反应 5.25h， 生成 6-甲氧基-1H-吲唑
  参考文献：
  名称：

  三甲基甲硅烷基重氮甲烷锂与苯炔的[3 + 2]环加成反应可轻松合成3-三甲基甲硅烷基吲唑

  摘要：

  由卤代苯生成的三甲基硅烷基重氮甲烷甲烷与苯炔的[3 + 2]环加成反应以良好至中等的收率得到了相应的3-三甲基硅烷基吲唑。

  DOI：

  10.1016/j.tetlet.2003.12.086
• 作为试剂：
  描述：

  2-氟-4-甲氧基苯甲醛 、 肼 在 二氯甲烷 、 水 、 Brine 、 乙酸乙酯 、 6-甲氧基-1H-吲唑 作用下， 反应 4.0h， 以to afford 6-methoxy-1H-indazole (intermediate 42) (568 mg, 59%) as a yellow solid的产率得到6-甲氧基-1H-吲唑
  参考文献：
  名称：

  Novel Functionally Selective Ligands of Dopamine D2 Receptors

  摘要：

  本发明涉及多巴胺D2受体的新型功能选择性配体，包括激动剂、拮抗剂和反向激动剂，其中图1为配体结构。本发明还涉及使用这些化合物治疗与D2受体相关的中枢神经系统疾病。

  公开号：

  US20130137679A1

文献信息

• P38 inhibitors and methods of use thereof
  申请人：——

  公开号：US20040192653A1

  公开（公告）日：2004-09-30

  This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.

  这项发明涉及p38的抑制剂，以及生产这些抑制剂的方法。该发明还提供了包括该发明的抑制剂的药物组合物，以及利用这些抑制剂和药物组合物在治疗和预防由p38介导的各种疾病中的方法。
• Palladium Catalyzed Hydrodefluorination of Fluoro-(hetero)arenes
  作者：Joseph J. Gair、Ronald L. Grey、Simon Giroux、Michael A. Brodney

  DOI：10.1021/acs.orglett.9b00889

  日期：2019.4.5

  of fluorine incorporation around metabolic hotspots, the corresponding deuterodefluorination reaction may prove useful for converting fluorinated libraries to deuterated analogues to suppress the oxidative metabolism by kinetic isotope effects.

  开发了钯催化的加氢脱氟以微调氟-（杂）芳族化合物的性能。可以在空气中建立鲁棒的反应，仅需要市售的组件，并且可以耐受与药物开发相关的各种杂环和功能。鉴于在代谢热点附近普遍存在氟掺入，相应的氘代氟化反应可证明可用于将氟化文库转化为氘代类似物，从而通过动力学同位素效应抑制氧化代谢。
• Arylindazoles and their use as herbicides
  申请人：Zeneca Limited

  公开号：US05444038A1

  公开（公告）日：1995-08-22

  This invention relates to substituted aryl indazoles, a process for producing them and their use as herbicides. In particular this invention relates to substituted aryl indazoles of the formula ##STR1## wherein all variables are as defined in the specification.

  这项发明涉及取代芳基吲唑，一种生产它们的方法以及它们作为除草剂的用途。特别是，这项发明涉及公式##STR1##中的取代芳基吲唑，其中所有变量如规范中定义的那样。
• JNK modulators
  申请人：Dunn James Patrick

  公开号：US20080146565A1

  公开（公告）日：2008-06-19

  Compounds of formula I modulate JNK: wherein the variables are as defined herein.

  式I的化合物调节JNK： 其中变量的定义如本文所述。
• [EN] COMPOUNDS AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DU FACTEUR INHIBITEUR DE LA MIGRATION DES MACROPHAGES
  申请人：IMMUNOPHAGE BIOMEDICAL CO LTD

  公开号：WO2020186220A1

  公开（公告）日：2020-09-17

  The present invention provides compounds of Formula (I) shown above and their pharmaceutically acceptable salt, solvates, isomers, or prodrugs, as well as pharmaceutical compositions containing these compounds. Also provided by the invention is a method for treating a disorder mediated by macrophage migration inhibitory factor in a subject, comprising administering to the subject in need thereof a compound or a pharmaceutical composition of this invention.

  本发明提供了上述公式(I)所示的化合物及其药用可接受的盐、溶剂化物、异构体或前药，以及含有这些化合物的药物组合物。本发明还提供了一种用于治疗由巨噬细胞迁移抑制因子介导的疾病的方法，包括向需要治疗的对象施用本发明的化合物或药物组合物。